Medical history has not wandered far from its original aspirations of being personalized.
Diagnostic capability has evolved from the metaphysical to the anatomical to the cellular and …

Personalized medicine has reached the mainstream, accounting for more new drug
approvals and a promising pipeline of candidate therapeutics. Recent advances in …

Foreword Waldman & Terzic advances in our understanding of the molecular mechanisms
contributing to pathogenesis have yielded an abundance of drug targets to individualize …

There have been several major problems that have plagued biopharmaceutical
development since the end of the 1990s, but two in particular have reached the point where …

On 1–2 December 2010 worldwide leaders in the field of co-diagnostics gathered in Boston,
MA, USA, to discuss the state of predictive medicine and the complexities of biomarker …

Optimally, any prescription should rely on an in-depth understanding of the disease biology
and the mechanism of action of the drug. However, despite the hype about precision …

As drug discovery and translational scientists think about using stratification with biomarkers
to improve the chances of getting medicines to patients, several areas of expertise need to …

Background Modern personalized medicine strategies builds on therapy companion
diagnostics to stratify patients into subgroups with differential benefit/risk. In general …

Low productivity in the pharmaceutical industry positions personalized medicine and
companion diagnostics as an attractive approach. The oncology community is enthusiastic …

The variability of pharmacotherapy can be of a significant magnitude, and the main reason
for this is often diseases heterogeneity. Patients who have similar diagnoses very often …